Monoclonal antibodies in the treatment of indolent lymphomas

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 1 SPEC. ISS., 2005, Pages 69-80

  Coiffier, Bertrand ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Follicular lymphoma; Indolent lymphomas; Monoclonal antibodies; Rituximab

Indexed keywords

ALEMTUZUMAB; APOLIZUMAB; CD20 ANTIGEN; CD22 ANTIGEN; CD52 ANTIGEN; CHLORAMBUCIL; CISPLATIN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IBRITUMOMAB TIUXETAN; INTERFERON; INTERLEUKIN 2 RECEPTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CYTOTOXICITY; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG UTILIZATION; FOLLICULAR LYMPHOMA; HUMAN; ISOTOPE LABELING; LYMPHOCYTOMA; LYMPHOMA; MAINTENANCE THERAPY; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA;

EID: 13344281000     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.016     Document Type: Review

References (67)

1. A.J. Grillo-Lopez C.A. White C. Varns et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma Seminars in Oncology 26 5 supplement 14 1999 66-73
2. M.L. Grossbard P. Fidias J. Kinsella et al. Anti-B4-blocked ricin: A phase II trial of 7 day continuous infusion in patients with multiple myeloma British Journal of Haematology 102 1998 509-515
3. M.S. Kaminski K.R. Zasadny I.R. Francis et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma Journal of Clinical Oncology 14 1996 1974-1981
4. T.E. Witzig C.A. White G.A. Wiseman et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 17 1999 3793-3803
5. D.G. Maloney T.M. Liles D.K. Czerwinski et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma Blood 84 1994 2457-2466
6. D.G. Maloney A.J. Grillolopez D.J. Bodkin et al. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma Journal of Clinical Oncology 15 1997 3266-3274
7. J.M. Foran A.Z.S. Rohatiner D. Cunningham et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma Journal of Clinical Oncology 18 2000 317-324
8. B. Coiffier C. Haioun N. Ketterer et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma. A multicenter phase II study Blood 92 1998 1927-1932
9. A. Demidem T. Lam S. Alas et al. Chimeric anti-CD20 (Idec-C2b8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biotherapy and Radiopharmaceuticals 12 1997 177-186
10. D. Shan J.A. Ledbetter & O.W. Press Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood 91 1998 1644-1652
11. D.M. Shan J.A. Ledbetter & O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunology and Immunotherapy 48 2000 673-683
12. M.A. Ghetie H. Bright & E.S. Vitetta Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin Blood 97 2001 1392-1398
13. S. Alas & B. Bonavida Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Research 61 2001 5137-5144
14. G. Cartron L. Dacheux G. Salles et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene Blood 99 2002 754-758
15. W.K. Weng & R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma Journal of Clinical Oncology 21 2003 3940-3947
16. R.J. Kreitman W.H. Wilson K. Bergeron et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia New England Journal of Medicine 345 2001 241-247
17. C.E. Dearden E. Matutes B. Cazin et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H Blood 98 2001 1721-1726
18. P. McLaughlin A.J. Grillo-Lopez B.K. Link et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program Journal of Clinical Oncology 16 1998 2825-2833
19. P. Campbell & R. Marcus Monoclonal antibody therapy for lymphoma Blood Reviews 17 2003 143-152
20. M. Reiser & V. Diehl Current treatment of follicular non-Hodgkin's lymphoma European Journal of Cancer 38 2002 1167-1172
21. Y. Cohen P. Solal-Celigny & A. Polliack Rituximab therapy for follicular lymphoma: A comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance Haematologica 88 2003 811-823
22. N.L. Berinstein A.J. Grillolopez C.A. White et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma Annals of Oncology 9 1998 995-1001
23. D.G. Maloney B. Smith & A. Rose Rituximab: Mechanism of action and resistance Seminars in Oncology 29 1 supplement 2 2002 2-9
24. M.R. Smith Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance Oncogene 22 2003 7359-7368
25. L. Van Der Kolk A. Grillo-Lopez J. Baars & M. Van Oers Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: Final report on safety and efficacy Leukemia 17 2003 1658-1664
26. E. Kimby Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-alpha 2a and granulocyte-macrophage colony stimulating factor Seminars in Oncology 29 2 supplement 6 2002 7-10
27. T.A. Davis A.J. Grillo-Lopez C.A. White et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of re-treatment Journal of Clinical Oncology 18 2000 3135-3143
28. Lemieux B. Bouafia F. Thieblemont C et al. Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: Efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematology Journal, in press.
29. S.J. Horning & S.A. Rosenberg The natural history of initially untreated low-grade non-Hodgkin's lymphomas New England Journal of Medicine 311 1984 1471-1475
30. K.M. Ardeshna P. Smith A. Norton et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial Lancet 362 2003 516-522
31. P. Colombat G. Salles N. Brousse et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation Blood 97 2001 101-106
32. J.D. Hainsworth H.A. Burris L.H. Morrissey et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma Blood 95 2000 3052-3056
33. J.D. Hainsworth S. Litchy H.A. Burris et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 20 2002 4261-4267
34. J.D. Hainsworth S. Litchy J.H. Barton et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology 21 2003 1746-1751
35. M. Ghielmini S.F. Schmitz S.B. Cogliatti et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly×4 schedule Blood 103 12 2004 4416-4423
36. Hainsworth JD, Litchy S, Greco FA. Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin's lymphoma (NHL) responding to single-agent rituximab: A randomized trial of the Minnie Pearl Cancer Research Network. Blood 2003; 102(1 supplement 69a): Abst. 231.
37. S. Paydas S. Yavuz U. Disel et al. Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase Leukemia and Lymphoma 44 2003 2165-2166
38. T. Igarashi Y. Kobayashi M. Ogura et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: A Japanese phase II study Annals of Oncology 13 2002 928-943
39. A. Conconi G. Martinelli C. Thieblemont et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type Blood 102 2003 2741-2745
40. M. Raderer G. Jager S. Brugger et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma Oncology 65 2003 306-310
41. I.M. Ghobrial & T.E. Witzig Waldenstrom macroglobulinemia Current Treatment Options in Oncology 5 2004 239-247
42. M.A. Dimopoulos C. Zervas A. Zomas et al. Treatment of Waldenstrom's macroglobulinemia with rituximab Journal of Clinical Oncology 20 2002 2327-2333
43. M.A. Gertz Waldenstrom's macroglobulinemia: A review of therapy Leukemia and Lymphoma 43 2002 1517-1526
44. M.A. Dimopoulos C. Zervas A. Zomas et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia Clinical Lymphoma 3 2002 163-166
45. M.S. Czuczman A.J. Grillo-Lopez C.A. White et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy Journal of Clinical Oncology 17 1999 268-276
46. M.S. Czuczman A. Fallon A. Mohr et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma Seminars in Oncology 29 1 supplement 2 2002 36-40
47. H. Schulz S.K. Klein U. Rehwald et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Blood 100 2002 3115-3120
48. R. Forstpointner A. Hanel R. Repp et al Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low Grade Lymphoma Study Group Deutsche Medizinische Wochenschrift 127 2002 2253-2258
49. W. Hiddemann M. Dreyling & M. Unterhalt Rituximab plus chemotherapy in follicular and mantle cell lymphomas Seminars in Oncology 30 1 supplement 2 2003 16-20
50. M. Herold G. Dolken F. Fiedler et al. Randomized phase III study for the treatment of advanced indolent non-Hodgkin's lymphomas (NHL) and mantle cell lymphoma: Chemotherapy versus chemotherapy plus rituximab Annals of Hematology 82 2003 77-79
51. Marcus R, Imrie K, Belch A. An international multi-centre, randomized, open-label, phase III trial comparing rituximab added to CVP chemotherapy to CVP chemotherapy alone in untreated stage III/IV follicular non-Hodgkin's lymphoma. Blood 2003; 102(1 supplement 28a): Abst. 87.
52. Hiddemann W, Dreyling MH, Forstpointner R et al. Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102(1 supplement 104a): Abst. 352.
53. A.M. Gianni M. Magni M. Martelli et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen) Blood 102 2003 749-755
54. J. Lundin E. Kimby M. Bjorkholm et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 2002 768-773
55. M.J. Keating I. Flinn V. Jain et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study Blood 99 2002 3554-3561
56. M. Uppenkamp A. Engert V. Diehl et al. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: A multicenter phase I/II study Annals of Hematology 81 2002 26-32
57. M.J. Keating B. Cazin S. Coutre et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed Journal of Clinical Oncology 20 2002 205-213
58. O. Gautschi N. Blumenthal M. Streit et al. Successful treatment of chemotherapy-refractory Sezary syndrome with alemtuzumab (Campath-1H) European Journal of Hematology 72 2004 61-63
59. J.P. Leonard M. Coleman J.C. Ketas et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 21 2003 3051-3059
60. O.W. Press J.M. Unger R.M. Braziel et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911 Blood 102 2003 1606-1612
61. B. Coiffier E. Lepage J. Brière et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma New England Journal of Medicine 346 2002 235-242
62. J.D. Shi C. Bullock W.C. Hall et al. In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells Leukemia and Lymphoma 43 2002 1303-1312
63. L.I. Gordon T.E. Witzig G.A. Wiseman et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma Seminars in Oncology 29 1 supplement 2 2002 87-92
64. T.E. Witzig L.I. Gordon F. Cabanillas et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 20 2002 2453-2463
65. M.S. Kaminski J. Estes K.R. Zasadny et al. Radioimmunotherapy with iodine I-131 tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience Blood 96 2000 1259-1266
66. J.M. Vose R.L. Wahl M. Saleh et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas Journal of Clinical Oncology 18 2000 1316-1323
67. E. Olsen M. Duvic A. Frankel et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma Journal of Clinical Oncology 19 2001 376-388